Nemonoxacin
Based on 1 publication(s) in Google Scholar
Nemonoxacin (TG-873870) is an orally active and potent broad-spectrum antibiotic. Nemonoxacin shows good inhibitory activity against different species of staphylococci, streptococci, and enterococci, Neisseria gonorrhoeae, and Haemophilus influenza. Nemonoxacin can be used in the study of bacterial infections and community-acquired pneumonia.
For research use only. We do not sell to patients.
- Purity: 99.77%
- CAS No.: 378746-64-6
- Formula: C20H25N3O4
- Molecular Weight:371.43
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Nemonoxacin
MoreAll Antibiotic Isoforms
More
Biological Activity
Nemonoxacin (0-5.51 µM; 24 h) shows good antibacterial activity in vitro[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MSSA, MRSA
-
Concentration:0-5.51 µM (0-2048 µg/mL)
-
Incubation Time:24 h
-
Result:Inhibited MSSA and MRSA with MIC90 values of 0.12 and 4 µg/mL.
Nemonoxacin (p.o.; 6, 12 and 24 h after infection) shows potent activities towards (2.5, 5, 10, 20 mg/kg) S. pneumonia 0613 (PRSP) and (10, 20, 40, 80 mg/kg) K. pneumonia 0607 infections in mouse pulmonary infection model[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CD-1 ICR mice (18-22 g; mouse systemic infection model)[2].
-
Dosage:1.6-4.0 mg/kg (S. aureus and S. capitis infections), 2.4-10.0 mg/kg (S. pneumonia infections), 5.0-22.6 mg/kg (E. faecalis infections), 1.6-10.0 mg/kg (E. coli infections)
-
Administration:Oral administration; 15 min and 6 h after infection
-
Result:Showed the ED50s of 2.08, 2.59 and 2.52 mg/kg to against S. aureus ATCC 29213 (MSSA), S. aureus 0705 (MRSA) and S. capitis 0687 (levofloxacin-resistant MRSC), respectively.
-
Animal Model:CD-1 ICR mice (18-22 g; mouse pulmonary infection model)[2].
-
Dosage:2.5, 5, 10, 20 mg/kg (S. pneumonia 0613 (PRSP)); 10, 20, 40, 80 mg/kg (K. pneumonia 0607)
-
Administration:Oral administration; 6, 12 and 24 h after infection
-
Result:Significantly decreased colony counts in vivo.
Chemical Information
-
CAS No. 378746-64-6
-
Appearance Solid
-
Molecular Weight 371.43
-
Formula C20H25N3O4
-
Color White to off-white
-
SMILES
O=C(C1=CN(C2CC2)C3=C(C=CC(N4C[C@@H](N)C[C@H](C)C4)=C3OC)C1=O)O
-
Synonyms
TG-873870
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
Solvent & Solubility
DMSO : 2 mg/mL (5.38 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Adam HJ, et al. In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates. Antimicrob Agents Chemother. 2009 Nov;53(11):4915-20. [Content Brief]
[2]. Li CR, et al. In vivo antibacterial activity of nemonoxacin, a novel non-fluorinated quinolone. J Antimicrob Chemother. 2010 Nov;65(11):2411-5. [Content Brief]
[3]. Lauderdale TL, et al. Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates. Antimicrob Agents Chemother. 2010 Mar;54(3):1338-42. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6923 mL | 13.4615 mL | 26.9230 mL | 67.3074 mL |
| 5 mM | 0.5385 mL | 2.6923 mL | 5.3846 mL | 13.4615 mL |
Powered by Bioz